Trials / Completed
CompletedNCT03289273
Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
REFINE: Regorafenib Observational Study in Hepatocellular Carcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,010 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regorafenib (Stivarga, BAY73-4506) | As per the treating physicians discretion |
Timeline
- Start date
- 2017-09-13
- Primary completion
- 2022-01-31
- Completion
- 2022-06-21
- First posted
- 2017-09-20
- Last updated
- 2023-06-13
Locations
37 sites across 21 countries: United States, Argentina, Austria, Belgium, Canada, China, Denmark, Egypt, France, Greece, Italy, Japan, Netherlands, Russia, Saudi Arabia, South Korea, Spain, Sweden, Taiwan, Thailand, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT03289273. Inclusion in this directory is not an endorsement.